Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BENEVOLENTAI BIO LIMITED manages a portfolio with 6 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 6 distinct examiners and 3 distinct art units. This distribution suggests a variety of biological or pharmaceutical technologies being prosecuted simultaneously.
NGUYEN, PETER is identified as the busiest examiner for the company. This examiner is currently responsible for 1 busiest examiner pending office action. Given that there are 6 pending office actions in total, the workload is distributed across the examiners, with each managing a single action. This decentralized structure requires the applicant to manage multiple examiner relationships simultaneously.
The presence of 3 distinct art units indicates that the company's patent applications are being reviewed by multiple specialized groups within the USPTO. This structural variety in prosecution, combined with the multiple examiners, requires the company to maintain a cohesive legal strategy while addressing the specific technical requirements of each art unit within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, PETER | 1 | — | — |
| MORALES, PEDRO JESUS | 1 | 61.5% | +55.6% |
| PLAYER, ROBERT AUSTIN | 1 | 14.3% | +33.8% |
| NEGIN, RUSSELL SCOTT | 1 | 55.9% | +34.2% |
| AUGER, NOAH ANDREW | 1 | 36.4% | +42.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623929 | IDENTIFYING ONE OR MORE COMPOUNDS FOR TARGETING A GENE | AUGER, NOAH ANDREW | 35d overdue |
| 17782058 | PRIORITISING BIOLOGICAL TARGETS | PLAYER, ROBERT AUSTIN | 4d overdue |
| 18326181 | METHOD FOR DETERMINING A MEASURE OF RELATIVE GENE EXPRESSION | NGUYEN, PETER | — |
| 18007391 | GRAPH PATTERN INFERENCE | MORALES, PEDRO JESUS | — |
| 17772180 | DESIGNING A MOLECULE AND DETERMINING A ROUTE TO ITS SYNTHESIS | NEGIN, RUSSELL SCOTT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623929 | IDENTIFYING ONE OR MORE COMPOUNDS FOR TARGETING A GENE | AUGER, NOAH ANDREW | 35d overdue |
| 17782058 | PRIORITISING BIOLOGICAL TARGETS | PLAYER, ROBERT AUSTIN | 4d overdue |
| 18007391 | GRAPH PATTERN INFERENCE | MORALES, PEDRO JESUS | — |
| 17772180 | DESIGNING A MOLECULE AND DETERMINING A ROUTE TO ITS SYNTHESIS | NEGIN, RUSSELL SCOTT | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| 2124 | 1 |
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18326181 | METHOD FOR DETERMINING A MEASURE OF RELATIVE GENE EXPRESSION | NGUYEN, PETER | — | §101§102§103 | Non-Final OA | — | Pending | May 31, 2023 |
| 18007391 | GRAPH PATTERN INFERENCE | MORALES, PEDRO JESUS | 2124 | §101§103 | Final Rejection | — | Pending | Jan 30, 2023 |
| 17782058 | PRIORITISING BIOLOGICAL TARGETS | PLAYER, ROBERT AUSTIN | 1686 | §101§103§112 | Non-Final OA | 4d overdue | Pending | Jun 02, 2022 |
| 17772180 | DESIGNING A MOLECULE AND DETERMINING A ROUTE TO ITS SYNTHESIS | NEGIN, RUSSELL SCOTT | 1686 | §101§103 | Final Rejection | — | Pending | Apr 27, 2022 |
| 17623929 | IDENTIFYING ONE OR MORE COMPOUNDS FOR TARGETING A GENE | AUGER, NOAH ANDREW | 1687 | §101§103§112 | Non-Final OA | 35d overdue | Pending | Dec 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial